{"version":"1.0","type":"link","title":"Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.","author_name":"Lowy JA 외","author_url":"https://prs-insight.online/author/Lowy%20JA","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/77440","thumbnail_width":1200,"thumbnail_height":630}